標(biāo)題: Titlebook: Clinical Trials in Neurology; Roberto J. Guiloff (Consultant Neurologist) Book 2001 Springer-Verlag London 2001 Ethical Issues.Parkinson.c [打印本頁] 作者: bradycardia 時間: 2025-3-21 18:37
書目名稱Clinical Trials in Neurology影響因子(影響力)
書目名稱Clinical Trials in Neurology影響因子(影響力)學(xué)科排名
書目名稱Clinical Trials in Neurology網(wǎng)絡(luò)公開度
書目名稱Clinical Trials in Neurology網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Clinical Trials in Neurology被引頻次
書目名稱Clinical Trials in Neurology被引頻次學(xué)科排名
書目名稱Clinical Trials in Neurology年度引用
書目名稱Clinical Trials in Neurology年度引用學(xué)科排名
書目名稱Clinical Trials in Neurology讀者反饋
書目名稱Clinical Trials in Neurology讀者反饋學(xué)科排名
作者: dominant 時間: 2025-3-22 00:19 作者: 不成比例 時間: 2025-3-22 03:39 作者: 江湖騙子 時間: 2025-3-22 06:43 作者: 溝通 時間: 2025-3-22 09:18
Drug Regulatory Requirements in the United Statesr-state commerce) unless it is the subject of an approved New Drug Application (NDA). The requirement for an NDA is the linchpin of the federal system of pre-market clearance of new drug products that operates within the United States.作者: 污穢 時間: 2025-3-22 13:38 作者: 污穢 時間: 2025-3-22 17:33 作者: 高射炮 時間: 2025-3-23 00:52
Analysis of Results: Statistical Principlesled clinical trial, even an effective treatment accounts for only a small portion of the resulting range and variability of clinical measurements. In other words, there is usually a lot of “noise” in the data. Ultimately, a mass of data must be condensed into quantities (statistics) which can be use作者: 討好美人 時間: 2025-3-23 03:55 作者: Capture 時間: 2025-3-23 08:24
The Intention-to-Treat Principle for Clinical Trialsization that distinguishes the controlled clinical trial from other forms of medical research. During the 1920s, R. A. Fisher developed the concept of randomization as a method of assigning “treatments” to blocks or plots of land in agricultural experiments [2]. Sir Austin Bradford Hill, considered 作者: 教義 時間: 2025-3-23 10:37
Statistical Analysis of Repeated-Measures Data with Drop-outst arises in this context is missing data caused by subjects dropping out prior to the end of the study. For earlier discussions of this topic, see Heyting et al. [1], Gornbein et al. [2], Little and Schenker [3] or Little [4]. This chapter reviews some approaches to statistical analysis when faced w作者: Figate 時間: 2025-3-23 14:40 作者: 微生物 時間: 2025-3-23 21:05
Outcome Variables in Dementia Trials: Conceptual and Practical Issuesal clinical scales and functional scales) in evaluating treatments for dementia, most especially Alzheimer’s disease (AD), with emphasis on neuropsychological assessment in trials of drugs designed to treat cognitive symptoms. We begin with a brief overview of issues in the diagnosis of dementia. We作者: rheumatism 時間: 2025-3-24 01:50 作者: conference 時間: 2025-3-24 04:07 作者: 滑動 時間: 2025-3-24 07:02
Fidel Aznar,Mar Pujol,Ramón Rizotatus and developing trends. This is all that will be attempted in this chapter. More extensive coverage of various statistical issues affecting drug development will be found in Senn [6]. The European Statistical Guideline [7] and International Conference on Harmonisation E9 Guideline are also extr作者: –LOUS 時間: 2025-3-24 11:36 作者: 證明無罪 時間: 2025-3-24 17:35
Parallelisation of the PC Algorithmmation on nonrespondents, namely maximum likelihood based on repeated-measures models, and multiple imputation. Methods are illustrated on an intent-to-treat analysis of data from a randomized clinical trial for tacrine in the treatment of Alzheimer’s disease, reported in detail in Little and Yau [5作者: 歡樂東方 時間: 2025-3-24 20:04
Tamarafinide V. Dittimi,Ching Y. Suenically, yet in life the diagnosis can usually only be made clinically. Moreover, the considerable heterogeneity and broad spectrum of impairment that occurs is difficult to measure in a reliable way. From the earliest clinical trials in AD, drug regulatory authorities, and particularly the US Food a作者: AWL 時間: 2025-3-25 00:22
Advances in Artificial Intelligencethrombolytic therapy [12] in cerebral infarction. There are trials in progress of many other potentially promising treatments such as angioplasty for symptomatic carotid stenosis [13] and neuroprotective treatments for acute ischaemic stroke [3].作者: Psychogenic 時間: 2025-3-25 05:17
Statistical Issues in Clinical Trials in Neurologytatus and developing trends. This is all that will be attempted in this chapter. More extensive coverage of various statistical issues affecting drug development will be found in Senn [6]. The European Statistical Guideline [7] and International Conference on Harmonisation E9 Guideline are also extr作者: crockery 時間: 2025-3-25 11:26
Analysis of Results: Statistical Principlesability of a statistic at least as large as that found in the trial . (null hypothesis). If the . value falls below a given threshold of improbability (.-level) under the assumption of no treatment effect, we are led to conclude that the lack of a treatment effect is implausible. For example, the fi作者: 寬容 時間: 2025-3-25 12:18 作者: Mhc-Molecule 時間: 2025-3-25 17:12
Dementia: Trial Design and Experience with Large Multicentre Trialsically, yet in life the diagnosis can usually only be made clinically. Moreover, the considerable heterogeneity and broad spectrum of impairment that occurs is difficult to measure in a reliable way. From the earliest clinical trials in AD, drug regulatory authorities, and particularly the US Food a作者: 我邪惡 時間: 2025-3-25 20:06
Cerebrovascular Disease: Basic Designs, Sample Sizes and Pitfallsthrombolytic therapy [12] in cerebral infarction. There are trials in progress of many other potentially promising treatments such as angioplasty for symptomatic carotid stenosis [13] and neuroprotective treatments for acute ischaemic stroke [3].作者: 單調(diào)女 時間: 2025-3-26 02:16
Book 2001with the ethical aspects, drug development and regulatory requirements, basic trial designs and the statistics used. A diseases section tackles specific aspects of disorders, focusing on the relevant ethical issues, outcome variables and experience with large multicentre trials.作者: CRUC 時間: 2025-3-26 05:02
icacy of neurological trials by improving trial design.Clinical Trials in Neurology. comprehensively tackles the methodology and design of clinical trials in neurological disease. A general section deals with the ethical aspects, drug development and regulatory requirements, basic trial designs and 作者: Predigest 時間: 2025-3-26 12:31
Omar O. Elrawy,Tamer S. Hamza,Samir S. Hosnyand unobservable variables such as disability, mood and health-related quality of life. In this chapter we begin by defining measurement and outlining the advantages of using standardised measurement methods. Then, we explain why it is important to measure variables such as disability and how they can be measured rigorously using Likert scales.作者: 留戀 時間: 2025-3-26 16:11 作者: modish 時間: 2025-3-26 18:21 作者: 解脫 時間: 2025-3-26 23:51
Assessment Measures and Clinical Scalesand unobservable variables such as disability, mood and health-related quality of life. In this chapter we begin by defining measurement and outlining the advantages of using standardised measurement methods. Then, we explain why it is important to measure variables such as disability and how they can be measured rigorously using Likert scales.作者: biopsy 時間: 2025-3-27 03:26 作者: sinoatrial-node 時間: 2025-3-27 07:01 作者: ELATE 時間: 2025-3-27 10:04 作者: 無價值 時間: 2025-3-27 16:51 作者: Digitalis 時間: 2025-3-27 18:53
Advances in Artificial Intelligenceby many to be the father of the randomized clinical trial [3], later applied the concepts of randomization to the field of medicine during the 1940s. Hill’s viewpoint, which now has wide acceptance, was that randomized clinical trials are necessary for the valid assessment of therapeutic efficacy [4].作者: LATE 時間: 2025-3-28 00:16
Lecture Notes in Computer Science then review the desirable characteristics of instruments for evaluating dementia treatments, followed by a discussion of specific cognitive and other assessment instruments along with data on the extent to which they meet certain desirable validity, reliability and practicality criteria we detail below.作者: 鑒賞家 時間: 2025-3-28 05:19
César García-Díaz,Arjen van Witteloostuijntrying to harmonise the requirements for developing and marketing drugs, which includes harmonising the requirements for GCP. A harmonised guideline for GCP was issued in 1996 for implementation in Europe from 17 January 1997.作者: 銼屑 時間: 2025-3-28 08:49 作者: 未完成 時間: 2025-3-28 14:21
Ethics, Outcome Variables and Clinical Scales: The Clinician’s Point of Viewshould predominate in such instances. In terms of the Declaration of Helsinki: “Concern for the interest of the subject must always prevail over the interests of science and society” [1,2]. The ethical aspects of research in neurology in no way differ from those in most other branches of medicine.作者: IST 時間: 2025-3-28 18:13 作者: 漂亮才會豪華 時間: 2025-3-28 21:48
The Intention-to-Treat Principle for Clinical Trialsby many to be the father of the randomized clinical trial [3], later applied the concepts of randomization to the field of medicine during the 1940s. Hill’s viewpoint, which now has wide acceptance, was that randomized clinical trials are necessary for the valid assessment of therapeutic efficacy [4].作者: 有機體 時間: 2025-3-29 00:34 作者: Constant 時間: 2025-3-29 07:02 作者: Scintillations 時間: 2025-3-29 10:49 作者: 躺下殘殺 時間: 2025-3-29 11:55
http://image.papertrans.cn/c/image/228262.jpg作者: 圖表證明 時間: 2025-3-29 18:27
Omar O. Elrawy,Tamer S. Hamza,Samir S. Hosnyntions. To justify this important role in research these measurement methods must demonstrate that they are reliable and valid indicators of abstract and unobservable variables such as disability, mood and health-related quality of life. In this chapter we begin by defining measurement and outlining作者: Pde5-Inhibitors 時間: 2025-3-29 23:26
Basma Elbeah,Abeer Elshater,Ahmed Toamaommunity. Some important rules for conduct of scientific research, e.g. clinical trials, arise from these obligations. Occasionally there may be a conflict between the different kinds of loyalty that medical scientists are supposed to cultivate. Obviously the obligations towards individual patients 作者: 懸崖 時間: 2025-3-30 03:14
Olivier Brandoy,Philippe Mathieurs ago [1]. Effective drugs were, however, sparse until this century despite the advances of civilisation and science. Many ineffective remedies survived, the early physicians and patients being deluded by the self-limiting nature of many diseases and the “placebo effect”. Progress was often precipi作者: Influx 時間: 2025-3-30 07:22
Alexander Gorobets,Bart Nooteboom undertake clinical trials without obtaining official approval and could market a product once the manufacturer was satisfied with the data which had been obtained. The only official controls came through the various poison control measures and through the Therapeutic Substances Act which set out re作者: 束縛 時間: 2025-3-30 08:56 作者: 決定性 時間: 2025-3-30 15:35
César García-Díaz,Arjen van Witteloostuijnand the data are accurate and credible. Guidance for quality control procedures and data monitoring for clinical trials has evolved through the development of Good Clinical Practice (GCP) standards. There are many GCP guidelines used in the world, which has resulted in many different standards of GC作者: headway 時間: 2025-3-30 18:57
Fidel Aznar,Mar Pujol,Ramón Rizotherefore, that the reader already has considerable familiarity with descriptive and inferential statistics and, in addition to knowing about means, medians, variances and standard deviations, has encountered the general framework of hypothesis tests, confidence intervals and so forth and particular作者: Fermentation 時間: 2025-3-30 23:18
Oscar Luaces ,José A. Gámez,Emilio Corchadoled clinical trial, even an effective treatment accounts for only a small portion of the resulting range and variability of clinical measurements. In other words, there is usually a lot of “noise” in the data. Ultimately, a mass of data must be condensed into quantities (statistics) which can be use作者: 相符 時間: 2025-3-31 04:24
Fidel Aznar,Mar Pujol,Ramón Rizotime intervals start at a starting time (or starting point), and end at an end time (or end point). In a clinical trial, the starting time is usually the date on which a patient joined the trial. The end time is typically the death date of the patient or the end date of the trial, whichever is soone作者: BILIO 時間: 2025-3-31 06:44
Advances in Artificial Intelligenceization that distinguishes the controlled clinical trial from other forms of medical research. During the 1920s, R. A. Fisher developed the concept of randomization as a method of assigning “treatments” to blocks or plots of land in agricultural experiments [2]. Sir Austin Bradford Hill, considered 作者: 隨意 時間: 2025-3-31 12:14 作者: Myelin 時間: 2025-3-31 15:04
Advances in Artificial Intelligencengly acknowledged by health care professionals, researchers and policy makers. Faced with unmanageable amounts of information, these groups require reliable summaries of research on which to base clinical and policy decisions [1] and to guide future research.作者: ATRIA 時間: 2025-3-31 20:26
Lecture Notes in Computer Scienceal clinical scales and functional scales) in evaluating treatments for dementia, most especially Alzheimer’s disease (AD), with emphasis on neuropsychological assessment in trials of drugs designed to treat cognitive symptoms. We begin with a brief overview of issues in the diagnosis of dementia. We作者: Contort 時間: 2025-4-1 01:34 作者: labile 時間: 2025-4-1 02:15
Advances in Artificial Intelligence and the United States [1]. There is a clear need for more effective treatments both to prevent stroke and to treat the acute event. There has, in response to this, been a substantial increase in interest in the design, methodology and analysis of randomised controlled trials in cerebrovascular dise作者: sigmoid-colon 時間: 2025-4-1 09:12 作者: Diaphragm 時間: 2025-4-1 10:53
Sitabhra Sinha,Srinivas RaghavendraEvidence-based medicine is the process of systematically finding, evaluating and utilising updated and good-quality research as the basis for clinical decision making [1].
